Pancreatic cancer

RenovoRx Announces Studies that Further Advance the Science of Pancreatic Cancer Treatment Presented at the 2021 ASCO Gastrointestinal Cancers Symposium

Pancreatic cancer, Gastrointestinal cancer, Cancer
Wednesday, January 20, 2021 - 1:00pm

LOS ALTOS, Calif., Jan. 20, 2021 /PRNewswire/ -- RenovoRx , an innovator in targeted cancer therapy, today announced two research studies were presented at the 2021 ASCO Gastrointestinal Cancers Symposium that further advance the science of pancreatic cancer treatment.

Key Points: 
  • LOS ALTOS, Calif., Jan. 20, 2021 /PRNewswire/ -- RenovoRx , an innovator in targeted cancer therapy, today announced two research studies were presented at the 2021 ASCO Gastrointestinal Cancers Symposium that further advance the science of pancreatic cancer treatment.
  • In one presentation, preliminary data from the ongoing Phase III TIGeR-PaC Clinical Trial was used to investigate incidence of sepsis in pancreatic cancer patients.
  • "The data presented at the 2021 ASCO Gastrointestinal Cancers Symposiumindicates how the TIGeR-PaC trial is helping to advance the science for pancreatic cancer treatment beyond its primary goals," said Dr. Ramtin Agah, Chief Medical Officer and Co-Founder at RenovoRx.
  • Studies presented at 2021 ASCO Gastrointestinal Cancers Symposium:
    "Sepsis and pancreatic cancer: Biliary stents a significant risk factor in patients undergoing chemotherapy," presented by Michael J. Pishvaian, Charles Li, et al.

Provectus Biopharmaceuticals Announces Release of Preprint Manuscript Describing Preclinical Study of PV-10® Immunotherapy and Chemotherapy for Treatment of Pancreatic Cancer

Clinical medicine, Medicine, Cancer, Cancer treatments, Gemcitabine, Organofluorides, Pancreatic cancer, Chemotherapy regimen, Chemotherapy, Pancreatic tumor, Evofosfamide
Wednesday, January 20, 2021 - 12:00pm

Chemotherapy regimens that include gemcitabine are the standard of care for the treatment of pancreatic cancer.

Key Points: 
  • Chemotherapy regimens that include gemcitabine are the standard of care for the treatment of pancreatic cancer.
  • The manuscript, entitled Intralesional injection of Rose Bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors, is available at the following link: https://assets.researchsquare.com/files/rs-140621/v1/cb1df721-b58b-4f5d-... .
  • PV-10 treatment-mediated DAMP-release has been demonstrated in three different tumor types: melanoma, colon cancer, and now pancreatic cancer.
  • This suggested that increased pancreatic tumor burden, which diminished gemcitabine efficacy, was overcome when PV-10 was combined with gemcitabine.

2021 Global Pancreatic Cancer Clinical Trial Pipeline Highlights - ResearchAndMarkets.com

Health, Oncology, Clinical trials, Health sciences, Health, Clinical research, Drug discovery, Pharmaceutical industry, Design of experiments, Clinical trial, Pancreatic cancer, Andrew Biankin, COVID-19 drug development
Friday, January 15, 2021 - 6:26pm

The "Global Pancreatic Cancer Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pancreatic Cancer Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the most up-to-date information on key pipeline products in the global Pancreatic Cancer market.
  • It covers emerging therapies for Pancreatic Cancer in active clinical development stages including early and late stage clinical trials.
  • The report provides Pancreatic Cancer pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer

Biotechnology, Pharmaceutical, Health, Oncology, Drugs, Clinical medicine, Cancer treatments, Breast cancer, Orphan drugs, Protein-bound paclitaxel, Paclitaxel, Gemcitabine, Pancreatic cancer, FOLFIRINOX, Chemotherapy, Evofosfamide
Friday, January 15, 2021 - 1:03pm

The last drug to be approved in the first-line metastatic pancreatic cancer setting is Abraxane (nab-paclitaxel).

Key Points: 
  • The last drug to be approved in the first-line metastatic pancreatic cancer setting is Abraxane (nab-paclitaxel).
  • The initial response rate is promising, and thus far there has not been significant additive toxicity from AB680 to chemotherapy.
  • AB680 is currently in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer.
  • AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel.

CytRx Highlights Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Patients

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Gastrointestinal cancer, Pancreatic cancer, Clinical medicine, Orphan drugs, Drugs
Friday, January 15, 2021 - 1:00pm

Interim results of the three-cohort trials, known as QUILT 88, show median survival rates more than doubled that of the historic rate in patients with advanced metastatic pancreatic cancer (for which no other FDA approved treatment exists).

Key Points: 
  • Interim results of the three-cohort trials, known as QUILT 88, show median survival rates more than doubled that of the historic rate in patients with advanced metastatic pancreatic cancer (for which no other FDA approved treatment exists).
  • According to NantKwest and ImmunityBio, the current trials were based on the original Cancer Moonshot hypothesis and exploratory QUILT trials initiated in 2017.
  • Randomized Phase 2 trials (QUILT 88, Cohorts A and B) for first- and second-line metastatic pancreatic cancer are actively enrolling at three sites with more than 50 patients enrolled or being evaluated in QUILT 88 to date.
  • On the basis of our initial studies, we initiated our QUILT 88 randomized trials in metastatic pancreatic cancer and are pleased to present today those findings, including Cohort C survival rates.

ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

Clinical medicine, Breast cancer, FOLFIRINOX, Cancer treatments, Pancreatic cancer, Triple-negative breast cancer, Orphan drugs, Cancer, Chemotherapy, Devimistat, Pelareorep
Thursday, January 14, 2021 - 9:30pm

The trial will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.

Key Points: 
  • The trial will enroll approximately 18 patients who have received no prior chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.
  • FOLFIRINOX is one of the most commonly utilized first-line chemotherapy regimens for the treatment of pancreatic cancer.
  • Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas.
  • Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer.

NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials

Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer, Cancer Breakthroughs, Cancer research, Joe Biden, Pancreatic cancer, ABO, Clinical medicine, Medicine, Orphan drugs, Monoclonal antibodies, Pelareorep
Wednesday, January 13, 2021 - 11:01pm

The early collaborative Cancer Moonshot trials involved the combination of cell therapy and immunotherapeutics from multiple biotech and pharmaceutical companies, including NantKwest, ImmunityBio, Celgene, and Pfizer.

Key Points: 
  • The early collaborative Cancer Moonshot trials involved the combination of cell therapy and immunotherapeutics from multiple biotech and pharmaceutical companies, including NantKwest, ImmunityBio, Celgene, and Pfizer.
  • Based on the data from these trials, ImmunityBio is conducting a pivotal, three-cohort pivotal trial (QUILT 88) in metastatic pancreatic cancer.
  • A randomized Phase 2 study (QUILT 88, Cohorts A and B) for first- and second-line metastatic pancreatic cancer is actively enrolling at three sites.
  • On the basis of our initial studies, we initiated our QUILT 88 randomized trials in metastatic pancreatic cancer and are pleased to present today those findings, including Cohort C survival rates.

Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial

Lung cancer, Branches of biology, Non-small-cell lung carcinoma, Pancreatic cancer, Carcinoma, Neuregulin 1
Tuesday, January 12, 2021 - 9:01pm

National Cancer Center (NCC) Japan has agreed to provide RNA sequencing, funded in part by Merus, for eligible patients with pancreatic adenocarcinoma and patients with NSCLC to identify NRG1 fusions.

Key Points: 
  • National Cancer Center (NCC) Japan has agreed to provide RNA sequencing, funded in part by Merus, for eligible patients with pancreatic adenocarcinoma and patients with NSCLC to identify NRG1 fusions.
  • NCC Japan, established in 1962, is a leading medical institution in cancer treatment and research in Japan.
  • NCCHE, established in 1992, is one of the leading specialized cancer hospitals in Japan, treating over 9,000 new patients each year.
  • The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ other solid tumors.

Arcus Biosciences Announces New Employment Inducement Grants

Biotechnology, Pharmaceutical, Health, Oncology, Carbonyl compounds, Drugs, Organic compounds, Breast cancer, Protein-bound paclitaxel, Pancreatic cancer, Gemcitabine, Paclitaxel, Arcus
Tuesday, January 12, 2021 - 9:10pm

The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.

Key Points: 
  • The stock options were granted pursuant to the Companys 2020 Inducement Plan, which was approved by the Companys Board of Directors in January 2020 pursuant to the inducement exception under NYSE Listed Company Manual Rule 303A.08.
  • Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.
  • AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel.
  • For more information about Arcus Biosciences, please visit www.arcusbio.com .

Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium

Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Drugs, Clinical medicine, Organic compounds, Orphan drugs, Breast cancer, Protein-bound paclitaxel, Pancreatic cancer, Gemcitabine, Paclitaxel, FOLFIRINOX, Pelareorep
Monday, January 11, 2021 - 10:03pm

every two weeks has been selected for this portion of the study.

Key Points: 
  • every two weeks has been selected for this portion of the study.
  • 1,5
    ARC-8 is a Phase 1/1b study to evaluate safety and tolerability of AB680 + zimberelimab (AB122) + chemotherapy in patients with treatment-naive metastatic pancreatic adenocarcinoma.
  • AB680 is currently in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer.
  • AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel.